{
  "pmcid": "10027760",
  "sha256": "b4839ba610f02fe7764b4ef299bbb5fd2b53ebf0ea4b73fb93fe107635a7f84a",
  "timestamp_utc": "2025-11-09T21:51:10.221002+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.278851063829787,
    "reading_ease": 15.013666666666694,
    "word_count": 188
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Indocyanine Green and Technetium Nanocolloid for Sentinel Lymph Node Detection in Pediatric Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "15 pediatric patients were prospectively included"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at UMC Utrecht, 15 pediatric patients were prospectively included based on eligibility criteria."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients received preoperative ICG–TC injections, followed by lymphoscintigraphy and SPECT-CT imaging."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the feasibility of adding indocyanine green (ICG) to 99m technetium nanocolloid (ICG–TC) for sentinel lymph node (SLN) detection in pediatric patients."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the detection rate of SLNs, measured intraoperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "15 pediatric patients were prospectively included"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "SLNs were transcutaneously visible in 10/15 (67%) patients."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "SLNs were transcutaneously visible in 10/15 (67%) patients. Intraoperatively, 35/37 (95%) SLNs were fluorescent, and 37/37 (100%) were radioactive."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NL71166.041.20"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}